The Pharma Data

DECEMBER 30, 2020

The Feverish Pricing of MS Treatments. Towards the end of March, the FDA approved two new treatments for multiple sclerosis (MS): Mayzent (siponimod) and Mavenclad (cladribine). Drug treatments for MS have been climbing an expensive staircase for a number of years. Consumer News. But they come at a cost.

Treatment 52

Treatment FDA Approval Disease FDA 52

Drug Target Review

MARCH 3, 2025

The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. This approach has the potential to revolutionise clinical trial design and lead to more effective, personalised treatments.

Disease 52

Disease Treatment Therapies Cell Biology 52

Broad Institute

NOVEMBER 2, 2023

Established in 2013, the Bayer-Broad collaboration is uniquely structured to encourage close coordination and ongoing, face-to-face interactions between researchers at both organizations. Bayer’s established collaboration with the Broad Institute has already resulted in three clinical oncology candidates over the past decade.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

The Pharma Data

MARCH 25, 2021

mg administered subcutaneously (SC) every eight weeks is being evaluated for the treatment of moderate-to-severe osteoarthritis (OA) pain in adult patients for whom use of other analgesics is ineffective or not appropriate. In 2013, Pfizer and Lilly entered into a collaboration to develop and commercialize tanezumab. Tanezumab 2.5

Treatment 52

Treatment Therapies FDA Licensing 52

Drug Target Review

APRIL 4, 2024

Treatment with mesdopetam counteracted both these features of the psychosis model, ie, restored normal levels of synchronisation and reduced HFOs. In rodents, non-human primates, as well as humans, long-term treatment with levodopa has been associated with an increase in dopamine D3 receptor expression.

Disease 105

Disease Treatment Licensing Licensing 105

The Pharma Data

APRIL 17, 2021

Biogen’s expansion in China now includes treatment options approved for relapsing MS and spinal muscular atrophy. today announced that China’s National Medical Products Administration (NMPA) has approved TECFIDERA ® (dimethyl fumarate) for the treatment of relapsing multiple sclerosis (MS). About TECFIDERA ® (dimethyl fumarate) .

Treatment 52

Treatment Clinical Trials Disease Trials 52

Drug Target Review

NOVEMBER 6, 2023

Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. 2013); 108(3): 479-485. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

The Pharma Data

AUGUST 30, 2021

Approval marks an important transformation in the treatment of more than 13 million people suffering from chronic kidney disease in Japan. 4 Forxiga is the first ever approved medicine for the treatment of the disease in Japan. In 2013, AstraZeneca K.K. Both Companies will co-promote for the treatment of CKD.

Treatment 52

Treatment Trials Disease Clinical Trials 52

National Institute on Drug Abuse: Nora's Blog

AUGUST 28, 2024

Over the past two decades, substance use treatment admissions have increased among people aged 50 and over. Chronic pain is prevalent among older adults, and treatment for pain is less effective in this age group than it is in younger people; it negatively impacts quality of life and is a risk factor for cognitive decline and premature death.

Treatment 110

Treatment Research Disease Drugs 110

The Pharma Data

MARCH 25, 2021

mg administered subcutaneously (SC) every eight weeks is being evaluated for the treatment of moderate-to-severe osteoarthritis (OA) pain in adult patients for whom use of other analgesics is ineffective or not appropriate. In 2013, Pfizer and Lilly entered into a collaboration to develop and commercialize tanezumab. Tanezumab 2.5

Treatment 52

Treatment FDA Therapies Licensing 52

The Pharma Data

DECEMBER 21, 2020

21 December 2020 — AstraZeneca’s Tagrisso ( osimertinib ) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent. 0.23; p<0.0001).

Treatment 52

Treatment Trials Disease FDA 52

PLOS: DNA Science

MARCH 21, 2024

million price tag for the one-time infusion, and for the older siblings who contributed to developing the gene treatment, but were too sick to receive it. She passed away in 2013. ” I wonder what families will actually end of paying for the one-and-done treatment. million, a lot less than the MLD treatment.

Therapies 98

Therapies Clinical Trials DNA Trials 98

PPD

SEPTEMBER 25, 2023

Historically, clinical trial populations were almost exclusively comprised of white, male participants,  exacerbating gaps in knowledge of diseases and conditions , preventive factors and treatment effectiveness. In Asia , personalized and precision medicine has become the driving force behind transformative clinical trials.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

Drug Target Review

JUNE 12, 2023

With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. Can you provide a summary of the key findings and implications of the preclinical studies on ISM6331 for the treatment of advanced solid tumours?

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Treatment 52

Treatment DNA Trials Therapies 52

Eye on FDA

JUNE 14, 2023

But the numbers began to dwindle and 2013 was the last time the office even issued 12 letters within a year (it did 23 that year). The latest letter was issued for a website that promoted a treatment for hypercortisolemia in patients with Cushings Disease. The numbers plummet in 2014 until the record low last year of only 4 letters.

FDA 82

FDA Production Doctors Treatment 82

DrugBank

AUGUST 15, 2024

Financial Implications of High-Level Industry-Academic Collaborations Accelerated Time-to-Market The traditional drug development timeline, which can span over a decade, is a significant obstacle to delivering timely treatments to patients. Another example is the long-term partnership between Bayer and the Broad Institute of MIT/Harvard.

Drug Development 98

Drug Development Clinical Trials Drugs Therapies 98

The Pharma Data

NOVEMBER 11, 2020

There currently are no approved drug treatment options for this condition. Currently, the only approved treatments for an LPE are interventions such as chest tube drainage, and if unsuccessful, a surgical procedure. Corcoran J, Robert H, Najib MR (2013) “New therapeutic approaches to pleural infection” Curr Opin Infect Dis, 26:196–20.

Licensing 40

Licensing Licensing Treatment Pharma Companies 40

Eye on FDA

MARCH 7, 2024

Since 1983 with the passage of the Orphan Drug, there has been increased attention and focus to bringing new treatments into play for rare diseases, with increasing numbers of new orphan drug approvals seen between 2013-2022 according to the National Institutes of Health.

FDA 78

FDA Disease Government Drugs 78

PLOS: DNA Science

MAY 16, 2024

” I’ve long thought that SARS-CoV-2, or an immediate viral predecessor, emerged years before 2019 – at least as far back as 2013. • reveals viral vulnerability to inspire novel treatments. The evidence for an earlier origin lies in viral genome sequences, specifically bat coronavirus RaTG13.

Virus 98

Virus DNA RNA Vaccine 98

The Pharma Data

FEBRUARY 22, 2022

In 2013, she was appointed Finance Director of the Artémis Group. He is co-founder and non-executive board member of the Hartwig Medical Foundation (large scale DNA analyses) and is a board member of the Center for Personalized Cancer Treatment and leads several innovative precision oncology clinical trials.

Clinical Trials 52

Clinical Trials DNA Science Clinical Development 52

The Pharma Data

APRIL 27, 2021

Roche announces five new intended uses for key cardiac biomarkers to help identify cardiovascular risk, better diagnose patients and support early treatment. Early diagnosis and treatment can contribute to saving or improving people’s lives and could help healthcare systems save money.

Treatment 40

Treatment Disease Pharmaceuticals Therapies 40

Common Sense for Drug Policy Blog

JULY 9, 2023

Injection Drug Use in the EU "Among first-time clients entering specialised drug treatment in 2021, or most recent year available, with heroin as their primary drug, 19% (down from 38% in 2013) reported injecting as their main route of administration.

Drugs 40

Drugs Treatment 40

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. Molecular therapy 21 , 109-118 (2013). Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. Münch RC, et al.

Engineering 105

Engineering Virus Therapies Immune Response 105

The Pharma Data

JANUARY 12, 2021

Following an increase during most of the 20th century, the cancer death rate has decreased continuously from its peak in 1991 through 2018, with a total decrease of 31 percent due to reductions in smoking and improvements in early detection and treatment, translating to 3.2 percent during 2009 through 2013 to 5.5 to 5 percent overall.

Treatment 52

Treatment Research 52

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. 2013) 56, 2059-2073. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

The Pharma Data

JUNE 18, 2021

The European Commission (EC) has approved Aubagio ® (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS). The study consisted of a screening period (up to four weeks), followed by a double-blind treatment period (up to 96 weeks after randomization).

Treatment 40

Treatment Therapies Disease Trials 40

Drug Target Review

SEPTEMBER 4, 2023

Plants are not well exploited for the treatment of infectious agents, and inter-species biochemical processes and infectious agents habitat interaction are not well studied. 2013): Exploring the Trypanosoma brucei Hsp83 Potential as a Target for Structure Guided Drug Design, PLOS Neglected Tropical disease. Trends in Parasitology. (35):

Drugs 111

Drugs RNA DNA Disease 111

The Pharma Data

OCTOBER 23, 2020

breast cancer units between 2013 and 2018. The researchers found that the median age varied by treatment allocation (surgery: 76 years; PET: 84 years). Lynda Wyld, M.B.Ch.B., The propensity-matched analysis included 426 surgery and 240 primary endocrine therapy (PET) patients matched for age, fitness, and frailty.

Therapies 52

Therapies Treatment Research 52

Agency IQ

OCTOBER 20, 2023

FDA’s newest draft guidance lays out considerations for developing treatments for diabetic foot infections In a new draft guidance document released within weeks of a related clinical practice guideline, the FDA provides considerations for developing therapies to treat diabetic foot infections, focusing on Phase 3 efficacy trials.

FDA 40

FDA Treatment Trials Therapies 40

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Cell Mol Immunol 10(1):21-9 (2013). A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas. Chem Immunol Allergy 86:151-183 (2005).

Therapies 105

Therapies Engineering Molecular Biology Science 105

New Drug Approvals

SEPTEMBER 29, 2024

Both were reversed by treatment with COR388 ( 2020 AAIC abstract ). Gingipains also were reported to degrade ApoE, and 28 days of treatment with COR388 was claimed to reduce CSF ApoE fragments ( 2020 AAIC abstract ). gingivalis DNA and gingipains in CSF, blood, and saliva, before and after treatment. and Europe.

Small Molecule 62

Small Molecule DNA Disease Trials 62

FDA Law Blog: Drug Discovery

DECEMBER 13, 2023

Sasinowski — On December 12, 2023, FDA announced the creation of a new advisory committee specifically for treatments for genetic metabolic diseases, the Genetic Metabolic Diseases Advisory Committee, or “GeMDAC.” Drug development for these conditions has unique and complex challenges, therefore few treatments are available to patients.”

Disease 59

Disease Production FDA Drug Development 59

The Pharma Data

DECEMBER 30, 2020

“Our findings suggest that motor skill training in functional activities is an effective and efficient treatment that results in important short-term and long-term improvement in function in people with chronic low back pain,” said study lead author Linda Van Dillen.

Therapies 52

Therapies Treatment Doctors Research 52

LifeSciVC

OCTOBER 10, 2024

Relatlimab has been in the clinic since late 2013, where similar questions have existed about the mechanism due to an absence of disclosures of single-agent pharmacodynamic and efficacy data. Clear early signals of clinical activity in heavily pre-treated patients who have failed to respond or are no longer responding to any other treatment.

Therapies 66

Therapies Clinical Development Pharmacokinetics Treatment 66

The Pharma Data

NOVEMBER 18, 2021

The company has completed proof-of- conception studies by developing first- by- class impediments targeting preliminarily undruggable TFs for the treatment of idiopathic pulmonary fibrosis (IPF), Ewing’s Sarcoma, prostate cancer and facioscapulohumeral muscular dystrophy (FSHD). In certain countries outside theU.S.,

Molecular Biology 52

Molecular Biology Pharmaceuticals Laboratories Clinical Development 52

The Pharma Data

JANUARY 4, 2021

was granted with the “Breakthrough Therapy Designation Drug” by the Center for Drug Evaluation (CDE) and currently enter a phase III clinical trial for treatment of patients with small cell lung cancer (SCLC) with disease progression or recurrence after two lines of prior systematic chemotherapy. SHENZHEN, China , Jan.

Therapies 40

Therapies Clinical Trials Drug Development Drugs 40